Systemic Chemotherapy (e.g., VEC regimen)
Treatment for Retinoblastoma
Typical Dosage: e.g., Vincristine 1.5 mg/m2, Etoposide 150 mg/m2, Carboplatin 560 mg/m2
Effectiveness
85%
Safety Score
25%
Clinical Trials
150
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
e.g., Vincristine 1.5 mg/m2, Etoposide 150 mg/m2, Carboplatin 560 mg/m2
Time to Effect
1-2 months
Treatment Duration
6-12 months
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10,000
Monitoring:$45,000
Side Effect Mgmt:$20,000
Total Annual:$75,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEQALYs Gained
17
Outcome-Based Costs
Cost per Responder
$93,750
Cost per Remission
$100,000
Comparison vs Intra-arterial Chemotherapy (IAC)
Cost Difference
$-10,000/year
Less expensive
QALY Difference
-0.75 QALYs
Worse outcomes
Dominance
No dominance
Systemic Chemotherapy (e.g., VEC regimen) Outcomes
for Retinoblastoma
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+80%
Remission Rate
+75%
Common Side Effects
Myelosuppression
+90%
Hair loss (Alopecia)
+100%
Nausea/Vomiting
+80%
Peripheral Neuropathy (Vincristine)
+50%
Ototoxicity (Carboplatin)
+50%
Secondary Malignancies (rare)
+5%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov